Yongjun Sui, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 41, Room D702
- Bethesda, MD 20892-1578
- 240-760-6726
- suiy@mail.nih.gov
RESEARCH SUMMARY
Dr. Sui’s research focuses on the induction and maintenance of tissue resident T cells, mucosal antibody responses, and trained innate immunity in colorectal mucosa and respiratory tracts. She has optimized the synergistic effects of immune modulators and viral vectors, as well as mucosal delivery method to promote the quantity and quality of immune responses. Using rodent and non-human primate models, she has been translating these strategies into the development of mucosal vaccines, including but not limited to HIV and SARS-CoV-2. She is also interested in identifying innate and adaptive immune correlates of protection to improve the vaccine efficacy.
Areas of Expertise
Yongjun Sui, Ph.D.
Publications
Biography
Yongjun Sui, Ph.D.
Dr. Sui received her Ph.D. in pathology from Beijing Institute of Basic Medical Sciences in 1998 and completed her postdoctoral training at the University of Kansas Medical Center (2002-2005) and the University of Pittsburgh (2005-2008). She joined Vaccine Branch, NCI, as a staff scientist in 2008.
Dr. Sui received the 2019 NCI Director's Innovation Award, 14 Federal Technology Transfer Awards from 2010 to 2023, and the 2023 NCI Director's Award (Murine Papillomavirus Outbreak Response Team). Dr. Sui is a primary member of the National Cancer Institute’s Animal Care and Use Committee (NCI-ACUC).